CYP2C8 is the liver's primary enzyme for metabolizing paclitaxel¹¹ paclitaxel
paclitaxel: a widely-used taxane chemotherapy drug for breast, ovarian, and lung cancers and its newer cousin [cabazitaxel | cabazitaxel: a second-generation taxane used in castration-resistant prostate cancer after docetaxel failure]. It is also responsible for clearing rosiglitazone and pioglitazone (thiazolidinedione diabetes drugs), repaglinide (a short-acting insulin secretagogue), and the anti-malarial amodiaquine. Beyond drug metabolism, CYP2C8 converts arachidonic acid into [epoxyeicosatrienoic acids (EETs) | EETs: potent vasodilatory and anti-inflammatory lipid mediators with cardioprotective and neuroprotective effects], making it a dual-purpose enzyme in both pharmacology and endogenous lipid signaling.

The rs1341164 variant lies within an intron of CYP2C8 — it does not change any amino acid — but intronic SNPs can still matter by tagging haplotype blocks that alter splicing efficiency, mRNA stability, or transcription factor binding sites. The evidence for rs1341164 is currently emerging: a single pharmacogenomic study has directly tested it, and the broader *IG haplotype literature provides indirect mechanistic context.

The Mechanism

rs1341164 is located at chromosome 10, position 95,041,116 (GRCh38), in intron 8/9 of CYP2C8 (HGVS: NC_000010.11:g.95041116T>C). As a C allele carrier, you may be tagging a haplotype group with reduced CYP2C8 expression or catalytic efficiency. The *IG haplotype study by Saito et al.²² *IG haplotype study by Saito et al.
Saito Y et al. CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenet Genomics, 2007 found that CYP2C8 haplotypes harboring several intronic variations were associated with a 2.5-fold higher area under the curve (AUC) of the major paclitaxel metabolite 6α-hydroxypaclitaxel, consistent with reduced CYP2C8 clearance. Whether rs1341164 is a tag SNP for this haplotype group has not been formally confirmed.

The Evidence

The most direct evidence comes from a 2022 pharmacogenomics study of metastatic castration-resistant prostate cancer (mCRPC). Herrero Rivera et al.³³ Herrero Rivera et al.
Herrero Rivera D et al. Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel. Pharmacogenomics, 2022 analyzed 56 SNPs across five drug-metabolism genes in 67 cabazitaxel-treated patients and found that rs1341164 C allele carriers had significantly better overall survival (hazard ratio 0.53 in multivariate analysis). The most plausible interpretation is that C allele carriers clear cabazitaxel more slowly, resulting in higher drug exposure and better tumor kill — consistent with the *IG haplotype's reduced clearance phenotype.

Parallel evidence exists for paclitaxel: Hertz et al.⁴⁴ Hertz et al.
Hertz DL et al. Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy. Breast Cancer Res Treat, 2014 demonstrated in 412 breast cancer patients that CYP2C8 low-metabolizer status (combined *2, *3, *4 variants) increased peripheral neuropathy risk by 72% (HR 1.722, p=0.018). This raises the possibility that rs1341164 C-allele carriers — if they indeed clear paclitaxel more slowly — may face similar neurotoxicity risk, though this has not been directly studied.

Important caveat: The cabazitaxel study was small (n=67) and the authors explicitly described results as "hypothesis-generating." rs1341164 has no entry in ClinVar, no CPIC or DPWG guideline, and has not been replicated. The evidence level is emerging.

Practical Actions

The principal clinical implication is in taxane chemotherapy contexts (paclitaxel, docetaxel, cabazitaxel). If you carry the C allele and your oncologist is prescribing a taxane, this variant warrants discussion — not because it mandates dose changes, but because it may contribute to your overall CYP2C8 metabolizer phenotype. Formal pharmacogenomic testing using a certified panel (which covers the clinically established *2, *3, *4 alleles alongside less-characterized intronic variants) provides a more complete picture.

The EET-production aspect of CYP2C8 function is also relevant: since EETs are cardioprotective and vasodilatory, variants that alter CYP2C8 expression in vascular endothelium may modulate cardiovascular risk — though this pathway has not been directly studied for rs1341164.

Interactions

CYP2C8 activity interacts with CYP2C9 (encoded by the adjacent gene on chromosome 10q24.1) — inhibitors of one often affect the other. CYP2C8 is potently inhibited by gemfibrozil (a lipid-lowering drug), which can increase exposure to repaglinide by up to 8-fold; this interaction does not depend on rs1341164 genotype but is relevant context when CYP2C8 metabolizer phenotype is uncertain. For the EET pathway, rs1341164 may interact with soluble epoxide hydrolase (EPHX2) variants: CYP2C8 makes EETs and EPHX2 degrades them, so reduced CYP2C8 combined with reduced EPHX2 activity may alter EET balance in a cardiovascular-relevant direction.

CYP7A1¹¹ CYP7A1
Cytochrome P450 family 7, subfamily A, member 1 — encodes cholesterol 7α-hydroxylase, the rate-limiting enzyme converting cholesterol to bile acids in the liver controls the single most important route by which the body permanently removes cholesterol. Every day, cholesterol 7α-hydroxylase converts a portion of your liver's cholesterol pool into primary bile acids — cholic acid and chenodeoxycholic acid — which are secreted into the gut, aid fat digestion, and are partially excreted in feces. The rate of this reaction sets how efficiently your body can clear excess cholesterol from circulation.

The rs1457043 variant is an intronic C-to-T substitution at position 58,497,880 on chromosome 8 (GRCh38), within the CYP7A1 gene on the minus strand. It does not change the CYP7A1 protein sequence but sits within a haplotype block that includes functionally important promoter and enhancer variants. Multiple population studies have identified rs1457043 as a tag SNP that co-segregates with CYP7A1 expression differences and associated lipid phenotypes.

The Mechanism

As an intron variant²² intron variant
a DNA change within a non-coding intervening sequence; can affect splicing, mRNA stability, local chromatin structure, or expression through regulatory elements without altering the protein sequence directly, rs1457043 does not directly alter CYP7A1 enzyme function. Its clinical relevance derives from linkage disequilibrium³³ linkage disequilibrium
the non-random association of alleles at two loci; nearby variants tend to be inherited together on the same chromosomal segment, so a tag SNP can predict the state of nearby functional variants with functional CYP7A1 regulatory variants in the same haplotype block.

The most functionally important variants in this region are rs3808607 (a promoter SNP, -203A>C) and rs9297994 (a downstream enhancer SNP), which together produce more than 100-fold variation in hepatic CYP7A1 mRNA expression⁴⁴ more than 100-fold variation in hepatic CYP7A1 mRNA expression
Li et al. showed these two SNPs interact through long-range chromatin contacts — their combined genotype, not either alone, predicts CYP7A1 expression, LDL levels, and statin response. rs1457043 recombines more frequently with these promoter variants than do other CYP7A1 SNPs, suggesting it tags a partially independent segment of the haplotype structure. When CYP7A1 activity is reduced, less cholesterol is converted to bile acids, leading to cholesterol accumulation in the liver, compensatory LDL receptor downregulation, and elevated circulating LDL-cholesterol.

The T allele (plus strand) is the major allele globally (~57%) and predominates in European (~59%) and Latino (~70%) populations. The C allele (GRCh38 reference) is in the minority globally but is common in African (~57%) and East Asian (~57%) populations. CC homozygotes — those with two C alleles — show the highest association with adverse lipid profiles in studied populations.

The Evidence

Subclinical atherosclerosis and LDL-cholesterol: The most specific evidence comes from a case-control study in Mexico⁵⁵ a case-control study in Mexico
Vargas-Alarcón et al. CYP7A1 gene polymorphisms are associated with increased LDL-cholesterol levels and the incidence of subclinical atherosclerosis. Biomol Biomed, 2025 comparing 416 patients with subclinical atherosclerosis (coronary artery calcium > 0) against 1,046 controls. Seven CYP7A1 polymorphisms were analyzed; rs1457043 homozygous minor allele carriers showed elevated incidence of subclinical atherosclerosis and higher LDL-cholesterol levels compared with other genotypes (p < 0.05). The LD analysis additionally showed that rs1457043 recombines more frequently than neighboring SNPs, indicating it partially captures independent haplotype variation.

Acute coronary syndrome and dyslipidemia: A companion study by the same group examined 1,317 ACS patients and 1,046 controls⁶⁶ examined 1,317 ACS patients and 1,046 controls
Vargas-Alarcón et al. Associations of CYP7A1 gene polymorphisms with risk of acute coronary syndrome, plasma cholesterol, and incidence of diabetes. Biomedicines, 2024 in a Mexican population. While five neighboring variants (rs9297994, rs10504255, rs8192870, rs2081687, rs10107182) reached significance for ACS risk and dyslipidemia, rs1457043 was included in the analysis as part of the broader CYP7A1 haplotype survey.

Drug-induced hepatotoxicity: In Chinese patients receiving anti-tuberculosis medications, rs1457043 CT (plus-strand) heterozygotes⁷⁷ rs1457043 CT (plus-strand) heterozygotes
Chen et al. CYP7A1, BAAT and UGT1A1 polymorphisms and susceptibility to anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis, 2016 had OR 2.05 (95% CI 1.18–3.15, p=0.014) for hepatotoxicity compared with CC homozygotes. This finding, combined with haplotype G-C or G-A combinations showing OR 2.40 (95% CI 1.62–3.57), suggests that CYP7A1 haplotype variation modifies hepatic bile acid flux in ways that can amplify drug toxicity. This is distinct from the lipid phenotype and likely reflects CYP7A1's role in liver bile acid homeostasis during pharmacological challenge.

CYP7A1 expression and statin response context: Research on nearby functional variants demonstrates that long-range chromatin interactions between rs3808607 and rs9297994⁸⁸ long-range chromatin interactions between rs3808607 and rs9297994
Li et al. Interactions Between Regulatory Variants in CYP7A1 Promoter and Enhancer Regions Regulate CYP7A1 Expression. Circ Genom Precis Med, 2018 produce the largest known range of CYP7A1 expression variation — over 100-fold. These expression differences correlate with LDL levels, coronary artery disease risk, and statin response, establishing the biological plausibility of rs1457043's haplotype-tagged effects.

Practical Actions

For CC homozygotes, the evidence suggests reduced efficiency of cholesterol-to-bile-acid conversion. The most direct interventions either support bile acid synthesis (plant sterols, soluble fiber) or monitor the downstream LDL consequences. Statins — which indirectly upregulate CYP7A1 expression through cholesterol depletion and SREBP signaling — remain the most evidence-based intervention for elevated LDL; however, the CYP7A1 haplotype context (via linked variants) may affect statin response magnitude and warrants LDL monitoring.

Plant sterols and stanols (2–3 g/day) compete with cholesterol for intestinal absorption, reducing the cholesterol pool that CYP7A1 must handle and independently lowering LDL by 5–15%. Soluble fiber (psyllium, oat beta-glucan) binds bile acids in the gut, reducing enterohepatic recirculation and compelling the liver to synthesize more bile acids from cholesterol — effectively compensating for reduced CYP7A1 activity.

Interactions

rs1457043 is in the same haplotype block as rs3808607 (the CYP7A1 promoter SNP, also called -203A>C or -204A>C in older literature), rs8192870, rs9297994 (downstream enhancer), and rs3824260. Because these variants partially recombine from each other, the combination matters: individuals carrying rs1457043 CC alongside risk haplotypes at rs3808607 and rs9297994 are likely to have the most severely reduced CYP7A1 expression. Conversely, individuals with rs1457043 CC but protective haplotypes at the functional promoter/enhancer SNPs may have attenuated phenotypic consequences. Compound actions across this haplotype block would require genotype data from the functional variants (rs3808607 and rs9297994) as well.

Before your body can make the long-chain omega-3 and omega-6 fats that drive anti-inflammatory signaling, membrane integrity, and brain function, it must clear a biochemical bottleneck: the first desaturation step. The enzyme responsible is delta-6 desaturase (D6D)¹¹ delta-6 desaturase (D6D)
also called Δ6-desaturase; encoded by FADS2 on chromosome 11q12.2; the rate-limiting first step in both the omega-3 and omega-6 PUFA elongation cascades. Without adequate D6D activity, short-chain essential fats from plant foods — alpha-linolenic acid (ALA) from flaxseed and linoleic acid (LA) from most vegetable oils — cannot enter the elongation pathway and accumulate as unused precursors while downstream products like EPA, DHA, and arachidonic acid remain scarce.

rs174568 is an intronic variant in FADS2 that sits within a tightly linked haplotype block spanning the entire FADS gene cluster. The T allele tags a regulatory state associated with reduced FADS2 expression and lower delta-6 desaturase activity. Because D6D operates upstream of delta-5 desaturase (encoded by FADS1), reduced FADS2 activity compresses both fatty acid pathways simultaneously.

The Mechanism

Delta-6 desaturase catalyzes two rate-limiting reactions: - Omega-6 pathway: linoleic acid (LA, 18:2) → gamma-linolenic acid (GLA, 18:3n-6) - Omega-3 pathway: alpha-linolenic acid (ALA, 18:3n-3) → stearidonic acid (SDA, 18:4n-3)

Both GLA and SDA are then elongated before undergoing a second desaturation by delta-5 desaturase (FADS1), ultimately yielding arachidonic acid (AA), EPA, and DHA. The T allele at rs174568 impairs this first step. The result is accumulation of LA and ALA with reduced production of all downstream long-chain products. Critically, because this is the upstream bottleneck, even a normally functioning FADS1 cannot compensate — there is less substrate for it to work with.

The intronic location of rs174568 suggests a regulatory effect on FADS2 transcription rather than a coding change in the enzyme itself. The FADS cluster contains multiple SNPs in high linkage disequilibrium that collectively modulate expression levels of FADS1, FADS2, and FADS3, likely through shared regulatory elements and allele-specific methylation patterns.

The Evidence

rs174568 was included in a study of the FADS gene cluster in 224 individuals from Tangier Island²² study of the FADS gene cluster in 224 individuals from Tangier Island
Mathias et al. 2010, FADS genetic variants and omega-6 PUFA metabolism in a homogeneous island population, J Lipid Res, a genetically isolated European founder population providing a clean signal for variant effects. rs174568 was one of eight SNPs in strong linkage disequilibrium showing the same pattern: the minor allele consistently associated with decreased omega-6 PUFAs including arachidonic acid, with increased DGLA (the immediate precursor to AA). Effect sizes for the strongest FADS1-activity ratio associations reached p = 5.8 × 10⁻⁷ to 1.7 × 10⁻⁸.

A Bayesian genetic analysis in 761 Alaskan Eskimos Voruganti et al. 2012, Variants in CPT1A, FADS1, and FADS2 are associated with higher levels of estimated plasma and erythrocyte delta-5 desaturases, Front Genet³³ Voruganti et al. 2012, Variants in CPT1A, FADS1, and FADS2 are associated with higher levels of estimated plasma and erythrocyte delta-5 desaturases, Front Genet identified rs174568 with posterior probability >0.8 for a functional effect on estimated delta desaturase activity. The finding was replicated in an independent Mexican American cohort, confirming cross-ancestry functional relevance.

The broader evidence for FADS cluster variants is substantial: a systematic review of 132 studies including ~500,000 participants⁴⁴ systematic review of 132 studies including ~500,000 participants
Visioli et al. 2026, Genetic modulation of omega-3 and omega-6 PUFA metabolism and health outcomes, Food Funct found that FADS1/FADS2 minor allele carriers show approximately 40–60% lower LC-PUFA conversion efficiency compared to common allele homozygotes, with 14 studies showing significant gene-by-diet interactions. At this effect size, plant-based omega-3 intake cannot reliably substitute for preformed EPA and DHA.

Practical Actions

For T allele carriers: plant-based omega-3 sources — flaxseed oil, chia seeds, walnuts — supply ALA, but the first conversion step (ALA → SDA via FADS2) is impaired. This makes preformed EPA and DHA from marine or algae sources the most reliable way to maintain adequate long-chain omega-3 status. TT homozygotes are most affected and should target 2–4 g combined EPA+DHA daily; CT heterozygotes benefit from 1–2 g daily.

For the omega-6 pathway, reduced GLA production means arachidonic acid synthesis from dietary linoleic acid is also impaired. While this sounds paradoxically protective (less AA = less pro-inflammatory eicosanoids), it also means cell membranes may be enriched with unconverted LA — a pattern associated with elevated triglycerides in some studies.

Monitoring triglyceride levels is warranted, particularly for TT homozygotes with diets high in refined omega-6 oils.

Interactions

rs174568 is in high linkage disequilibrium with multiple SNPs across the FADS1-FADS2-FADS3 cluster, including rs174537 (FADS1), rs174547 (FADS1), rs174575 (FADS2), and rs1535 (FADS2). Carriers of multiple minor alleles in this cluster experience compounding impairment at both the FADS2 (D6D) and FADS1 (D5D) steps — a complete blockade of the endogenous LC-PUFA synthesis pathway.

The functional consequence is similar to the neighboring FADS1 variants (rs174537, rs174547) already in the database, but operates at the earlier delta-6 step rather than delta-5, affecting a wider range of PUFA products. Both FADS2 and FADS1 minor allele carriers should prioritize preformed EPA/DHA over plant-based omega-3 sources.

Type I collagen is the most abundant protein in bone, accounting for roughly 90% of the organic bone matrix¹¹ organic bone matrix
The protein framework that mineralizes to become hard bone. The COL1A1 gene encodes the alpha-1 chain, two of which combine with one alpha-2 chain to form the collagen triple helix. Deep within the first intron of COL1A1 lies a binding site for Sp1²² Sp1
A transcription factor that regulates collagen gene expression, a transcription factor that controls how much collagen your cells produce. The rs1800012 polymorphism — a single G-to-T change — alters this binding site, and that small change has rippled through decades of osteoporosis research.

The Mechanism

The T allele increases Sp1 binding affinity, leading to approximately three-fold higher abundance of transcripts from the T allele compared to the G allele in heterozygotes.

This might sound beneficial — more collagen transcription should mean stronger bones — but the reality is more complex.

Osteoblasts from individuals with the T allele produce an altered ratio of alpha-1 to alpha-2 collagen chains.

This disruption in collagen stoichiometry reduces the yield strength of bone , making it more brittle even when bone mineral density appears normal.

The polymorphism sits in a regulatory region³³ regulatory region
Intron 1 of COL1A1, previously shown to be critical for collagen transcription control that fine-tunes collagen production throughout life. During periods of high bone turnover — adolescence, pregnancy, menopause — the effects become particularly apparent.

The Evidence

The association between rs1800012 and bone health is one of the most thoroughly studied in skeletal genetics.

A meta-analysis of nearly 7,000 subjects found that heterozygotes (GT) had 1.26 times the odds of any fracture, while TT homozygotes had 1.78 times the odds, with the effect driven primarily by vertebral fractures (OR 1.37 for GT, 2.48 for TT).

Large-scale bone density studies⁴⁴ Large-scale bone density studies
The GENOMOS consortium analyzed over 20,000 participants across Europe confirmed modest but consistent reductions in BMD.

The TT genotype showed 21 mg/cm² lower BMD at the lumbar spine and 25 mg/cm² lower at the femoral neck compared to GG.

While these differences may seem small, they compound over decades.

The effect is sexually dimorphic and age-dependent.

Girls with the TT genotype have significantly lower BMD Z-scores before puberty completion, but this association attenuates after puberty.

The data suggest rs1800012 principally affects female bone density during periods of high turnover

— puberty and postmenopause — when the collagen scaffolding is being rapidly remodeled.

Interestingly, the same variant that increases osteoporosis risk appears protective for certain soft tissue injuries.

A meta-analysis found the rare TT genotype associated with reduced risk of sports-related tendon and ligament injuries (OR 0.17), particularly ACL tears, suggesting the altered collagen may be more flexible and resistant to acute trauma.

Practical Implications

If you carry one or two T alleles, your bones require more vigilant care, especially during high-turnover periods. Adequate calcium and vitamin D are non-negotiable — they're the raw materials your body uses to mineralize the collagen framework, and suboptimal intake compounds the structural disadvantage of altered collagen quality.

Calcium and vitamin D supplementation has been shown to suppress bone turnover, increase bone mass, and even reduce fracture incidence, with benefits observed even in young adults.

For TT homozygotes, consider maintaining 25-hydroxyvitamin D levels toward the higher end of the normal range (40-60 ng/mL) and ensuring calcium intake meets or exceeds recommendations (1,000-1,200 mg daily for adults).

Weight-bearing exercise⁵⁵ Weight-bearing exercise
Resistance training and impact activities that stimulate bone formation is equally critical, as mechanical stress signals osteoblasts to strengthen bone. However, the protective effect against soft tissue injuries suggests TT carriers may have a biomechanical advantage in certain athletic contexts — though bone fragility remains the dominant concern.

Postmenopausal women with the TT genotype should discuss baseline bone density screening with their physician, as they may benefit from earlier monitoring and proactive intervention if BMD declines.

Interactions

The rs1800012 polymorphism exists within a haplotype structure at the COL1A1 locus.

It's in strong linkage disequilibrium with rs1107946 and rs2412298, and these haplotypes show bidirectional regulation of BMD.

Individuals carrying multiple risk alleles across these linked variants may experience compounded effects on bone metabolism.

Beyond COL1A1 itself, bone health is influenced by variants in genes controlling calcium absorption (VDR, vitamin D receptor), bone resorption (TNFRSF11B/osteoprotegerin), and the RANK-RANKL-OPG pathway⁶⁶ RANK-RANKL-OPG pathway
The master regulatory system controlling osteoclast activity. While no formal compound implications have been established for rs1800012 plus other bone health SNPs, individuals with multiple genetic risk factors should be particularly proactive about bone-protective lifestyle measures.

FOXO3 is one of only two human genes — along with APOE — whose longevity associations have been consistently replicated across multiple independent populations and ancestries. The first FOXO3 signal, rs2802292¹¹ rs2802292
the well-characterized HSF1-binding enhancer variant in intron 2, has been studied intensively since 2008. But FOXO3's longevity architecture is more complex: rs1935949 tags a second, independent haplotype block spanning 121 kilobases of FOXO3 intron 3 that independently contributes to centenarian enrichment through a distinct regulatory mechanism.

Pawlikowska et al. 2009²² Pawlikowska et al. 2009
Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. Aging Cell. 2009 identified rs1935949 among longevity-associated variants across three Caucasian cohorts — the Study of Osteoporotic Fractures, the Cardiovascular Health Study, and Ashkenazi Jewish Centenarians — finding a significant longevity association in women (OR = 1.35, 95% CI 1.15–1.57, adjusted p = 0.0093).

The Mechanism

rs1935949 sits in intron 3 of FOXO3, approximately 1.7 kilobase-pairs from an intron-exon boundary, and is in strong linkage disequilibrium (r² = 0.96) with rs4946935 — the functionally characterized variant in the same haplotype block. Flachsbart et al. 2017³³ Flachsbart et al. 2017
Identification and characterization of two functional variants in the human longevity gene FOXO3. Nat Commun. 2017 demonstrated that the longevity allele of rs4946935 creates an allele-dependent binding site for serum response factor (SRF) — a transcription factor distinct from the heat shock factor 1 (HSF1) that binds the rs2802292 site. In luciferase reporter assays, the longevity alleles at rs4946935 (and by proxy, rs1935949) show substantial enhancer activity that is specifically reversed by IGF-1 treatment.

This IGF-1 reversibility is mechanistically significant. The insulin/IGF-1 signaling (IIS) pathway⁴⁴ insulin/IGF-1 signaling (IIS) pathway
the PI3K-AKT cascade that phosphorylates and excludes FOXO3 from the nucleus is the primary evolutionary brake on FOXO3 activity: high IGF-1 levels drive AKT activation, which phosphorylates FOXO3 and traps it in the cytoplasm, preventing it from activating stress-response and longevity genes. The longevity allele at rs1935949's haplotype creates an enhancer that is most active when IGF-1 is low — exactly the dietary and metabolic condition under which FOXO3's protective functions matter most. This explains why the variant was first identified in a study of IGF-1 signaling pathway genetics and why its effects are magnified by caloric restriction and fasting contexts.

An eQTL database search confirms that the longevity alleles associated with the rs1935949/rs4946935 haplotype block are associated with higher FOXO3 mRNA expression across multiple human tissues, consistent with the enhancer model. The haplotype containing rs1935949 (haplotype block 1, alongside rs13217795, rs2764264, rs9400239, and rs9486902, D'>0.86 spanning 121 kb) is structurally distinct⁵⁵ structurally distinct
the haplotype blocks were identified by LD analysis across 12 FOXO3 SNPs from the block containing rs2802292, allowing independent additive effects on longevity.

The Evidence

Bao et al. 2014⁶⁶ Bao et al. 2014
Association between FOXO3A gene polymorphisms and human longevity: a meta-analysis. Asian J Androl. 2014 pooled five of its eleven studies that genotyped rs1935949, encompassing 1,435 cases and 2,098 controls, finding significant overall longevity association (OR = 1.14, 95% CI 1.01–1.27). Gender-stratified results suggested the overall association was not driven primarily by females in this cohort, though the sex-specific picture is complex and differs across studies.

The largest replication effort comes from Bae et al. 2018⁷⁷ Bae et al. 2018
Effects of FOXO3 polymorphisms on survival to extreme longevity in four centenarian studies. J Gerontol A Biol Sci Med Sci. 2018, which analyzed 2,072 cases and 6,194 controls across the Long Life Family Study, New England Centenarian Study, Southern Italian Centenarian Study, and Longevity Genes Project. rs1935949 showed a meta-analysis beta of 0.18 (SE 0.044, p = 6.60×10⁻⁵), corresponding to approximately OR = 1.20 for extreme longevity (defined as surviving to the oldest 1 percentile of the 1900 U.S. birth cohort — ≥96 years for males, ≥100 for females). Centenarian enrichment of the protective A allele was observed in all four cohorts, though effect sizes varied.

Evidence is strongest in Caucasian populations. Studies in Chinese Han populations did not replicate the rs1935949 association, consistent with population-specific LD patterns and potentially different regulatory architectures across ancestries.

Practical Implications

The IGF-1-reversible nature of this haplotype's regulatory effect suggests a dietary angle that is more explicit than for rs2802292. Dietary interventions that lower circulating IGF-1 — particularly plant-protein-predominant diets and periodic fasting — reduce IGF-1-mediated suppression of FOXO3 at this enhancer. Caloric restriction extending maximum lifespan in model organisms is mechanistically connected to reduced IIS signaling and consequent FOXO3 activation; the rs1935949 haplotype may amplify this response.

The additive architecture of FOXO3 longevity signals is worth appreciating. Individuals who carry protective alleles at both rs1935949 and rs2802292 benefit from independent contributions to FOXO3 expression through distinct transcription factor binding sites (SRF at the rs4946935/rs1935949 haplotype; HSF1 at rs2802292). The two mechanisms respond to different cellular stresses — nutrient status for the IGF-1-sensitive haplotype, heat shock and oxidative stress for the HSF1 site — making them genuinely complementary.

Interactions

rs1935949 and rs2802292 are in different haplotype blocks across FOXO3 and have independent longevity effects. Individuals carrying protective alleles at both loci likely experience additive longevity benefit through distinct molecular mechanisms (SRF-mediated nutrient-sensing regulation vs. HSF1-mediated stress response regulation). A compound action is worth considering for individuals carrying beneficial alleles at both rsids, as the combined message — targeting both IGF-1 reduction and stress-response activation — is more specific than either alone.

rs4946935 (r² = 0.96 with rs1935949) is the functional proxy variant for the enhancer mechanism; individuals who have both in their genome data will likely have concordant results. rs13217795, also in haplotype block 1, has been separately shown to regulate an alternative FOXO3 promoter (FOXO3-TR isoform expression), adding another regulatory dimension to the same haplotype block.

Your heart's pumping power comes from millions of sarcomeres¹¹ sarcomeres
The sarcomere is the basic contractile unit of cardiac muscle. Each sarcomere contains an interdigitating lattice of thick (myosin) and thin (actin) filaments that slide past each other to produce contraction working in concert. The MYL3 gene encodes the essential myosin light chain (ELC), a structural component of the myosin thick filament that stabilizes the lever arm region and regulates the force and speed of cardiac muscle contraction. The Arg94His substitution — a single amino acid change replacing arginine with histidine at position 94 of the ELC — disrupts this regulation in a way that causes the heart muscle to thicken abnormally, a condition called hypertrophic cardiomyopathy (HCM).

HCM is the most common inherited cardiac disease, affecting approximately 1 in 500 people overall. However, MYL3 mutations are a rare cause of HCM — responsible for less than 1% of all sarcomeric HCM cases. The Arg94His variant in particular has been documented in a small number of families worldwide and is classified as pathogenic by eight independent clinical laboratories²² pathogenic by eight independent clinical laboratories
ClinVar VCV000031777: submissions from LabCorp Genetics, Women's Health and Genetics/LabCorp, Ambry Genetics, GeneDx, Mass General Brigham, NIH All of Us, Color Diagnostics, and CHEO Genetics.

The Mechanism

The MYL3 ELC wraps around the myosin heavy chain lever arm³³ lever arm
The lever arm is the portion of myosin that amplifies the small conformational change at the catalytic domain into a large stroke movement that pulls actin filaments. Light chains stabilize this lever arm against mechanical stress. Arginine-94 sits in a functionally critical region of the ELC. Replacing the positively charged arginine with histidine (which carries a smaller, uncharged side chain at physiological pH) is predicted to disrupt local protein folding and the ELC's interaction with the myosin heavy chain, altering the super relaxed state of myosin — a low-energy resting state that is disrupted in HCM-associated ELC mutations. The net result is hypercontractility of the sarcomere, leading over time to pathological left ventricular hypertrophy, diastolic dysfunction, and in some cases left ventricular outflow tract obstruction.

The Evidence

The primary evidence for MYL3 Arg94His comes from a Japanese family study⁴⁴ Japanese family study
Nomura et al., J Cardiol, 2016 (N=7 family members, 5 affected; followed by registry screening of 600 HCM patients) that used whole-exome sequencing combined with bioinformatic filtering to identify the variant. Among carriers in that family, disease penetrance was 88% — very high for an HCM gene. All clinically affected carriers showed asymmetric septal hypertrophy with a maximum left ventricular wall thickness of 18±3mm without outflow obstruction. Two additional carriers were found in a registry of 600 HCM patients, supporting that this is a genuine pathogenic variant rather than a private family mutation.

By contrast, other MYL3 variants (such as the p.Val79Ile variant⁵⁵ p.Val79Ile variant
Andersen et al., Biochem Res Int, 2012 — nine heterozygous carriers in a Danish family) show much lower penetrance (~40%) and late onset. This variability is consistent with the broader GeneReviews HCM data⁶⁶ GeneReviews HCM data
Cirino et al., updated 2025 — MYL3 overall penetrance ~32%, the lowest among sarcomeric HCM genes when all variants are pooled. The Arg94His variant appears to be at the higher end of MYL3 penetrance, based on the Nomura family data, though the evidence is limited to a small number of families. Eight independent clinical laboratories have independently classified it as pathogenic or likely pathogenic, providing strong multi-submitter validation.

In terms of population frequency, Arg94His is extremely rare: gnomAD v4 exomes identified only 7 T alleles among over 730,000 alleles examined globally, exclusively in European and Latino ancestry groups.

Practical Actions

For carriers of MYL3 Arg94His, the central priorities are: (1) confirm the diagnosis with a specialist, (2) establish regular cardiac surveillance, and (3) arrange cascade testing for first-degree relatives.

Unlike many common HCM genes (MYBPC3, MYH7) where genotype-specific prognosis is well-characterized, MYL3 Arg94His has been observed in relatively few families. Standard HCM management — echocardiography every 1–2 years, ambulatory ECG monitoring, exercise testing, and SCD risk stratification — applies. Drug therapy (beta-blockers, calcium channel blockers) addresses symptoms; septal reduction therapy (myectomy or alcohol ablation) is reserved for refractory obstructive cases. The newer selective cardiac myosin inhibitor mavacamten is approved for obstructive HCM and may be relevant if outflow obstruction develops.

Interactions

MYL3 variants have been observed to interact with other sarcomeric HCM genes. Individuals carrying two sarcomeric pathogenic variants (compound or digenic) show substantially worse outcomes — a hazard ratio of 7.5 for adverse events such as cardiac transplantation or ICD placement⁷⁷ hazard ratio of 7.5 for adverse events such as cardiac transplantation or ICD placement
Cirino et al., GeneReviews, 2025 — based on registry data across sarcomeric HCM genes compared to single-variant carriers. This means that if a carrier of MYL3 Arg94His also carries a pathogenic variant in MYBPC3, MYH7, TNNT2, or another sarcomeric gene, clinical severity is likely to be substantially greater.

MYL3 is an essential light chain (encoded by chromosome 3), distinct from the regulatory light chain encoded by MYL2. Variants in ACTC1 (cardiac actin, rs193922680) affect the thin filament partner of myosin and can produce overlapping HCM phenotypes through a different molecular mechanism.

Every time your body burns fat for energy during fasting, sleep, or prolonged exercise, it relies on a chain of enzymes inside the mitochondria. The first and rate-limiting step for very long-chain fatty acids (14–20 carbons) is carried out by very-long-chain acyl-CoA dehydrogenase¹¹ very-long-chain acyl-CoA dehydrogenase
VLCAD — encoded by ACADVL on chromosome 17p13. The enzyme sits on the inner mitochondrial membrane and initiates beta-oxidation of long-chain fatty acids, producing the acetyl-CoA and reduced electron carriers (FADH₂) that feed the Krebs cycle and electron transport chain. This SNP, rs200788251, represents a c.865G>A transition that replaces the glycine at position 289 with the much bulkier, positively charged arginine (p.Gly289Arg). Glycine-289 sits in a structurally conserved region of the enzyme and is under strong evolutionary constraint; the substitution reduces VLCAD activity to approximately 15% of normal in vitro.

The Mechanism

VLCAD²² VLCAD
very-long-chain acyl-CoA dehydrogenase, a homodimeric flavoprotein that removes two hydrogen atoms from the acyl-CoA thioester, generating a trans-2-enoyl-CoA and transferring electrons to electron transfer flavoprotein (ETF) for entry into the respiratory chain depends on precise folding of its active site for catalysis. The p.Gly289Arg substitution introduces a bulky, charged side chain where glycine's compact structure is required for proper protein folding. Functional studies demonstrate that fibroblasts from a compound heterozygous individual carrying the p.Gly289Arg allele alongside a second pathogenic variant showed no detectable enzyme activity and absent protein expression on western blot — indicating the substitution causes protein misfolding and accelerated degradation.

Because ACADVL operates as a homodimer, a single non-functional allele (the heterozygous carrier state) still produces enough functional enzyme dimers — with approximately 50% enzyme activity — to support normal fatty acid oxidation under ordinary dietary conditions. Disease emerges only when both alleles are compromised.

The Evidence

The variant is classified likely pathogenic by the ClinGen ACADVL Variant Curation Expert Panel³³ likely pathogenic by the ClinGen ACADVL Variant Curation Expert Panel
ClinVar VCV000370981, 4-star expert panel review, last evaluated June 2023, based on ACMG/AMP classification criteria. All twelve diagnostic laboratory submitters in ClinVar classify the variant as pathogenic or likely pathogenic. The glycine at codon 289 is conserved across vertebrates, computational tools (SIFT, PolyPhen-2) predict a deleterious effect, and in vitro functional studies confirm the consequence.

A US newborn screening study of 693 individuals⁴⁴ US newborn screening study of 693 individuals
Pena et al. Recurrent ACADVL molecular findings in individuals with a positive newborn screen for very long chain acyl-coA dehydrogenase (VLCAD) deficiency in the United States. Mol Genet Metab, 2016 identified p.Gly289Arg on six alleles from affected individuals, establishing it among the recurrent pathogenic alleles seen in clinical practice in the United States.

VLCAD deficiency occurs in approximately 1 in 30,000–100,000 births. Expanded newborn screening with acylcarnitine profiling — measuring C14:1 acylcarnitine⁵⁵ C14:1 acylcarnitine
tetradecadienoylcarnitine, the characteristic accumulation product of impaired VLCAD-mediated beta-oxidation; a C14:1 level above 1 µmol/L on dried blood spot strongly suggests VLCAD deficiency — now identifies most affected individuals presymptomatically.

Three phenotypes are documented in homozygous or compound heterozygous individuals: - Severe neonatal form: cardiomyopathy (hypertrophic or dilated), pericardial effusion, arrhythmia, and metabolic crisis in the first weeks of life — historically associated with significant mortality. - Infantile hepatic form: hypoketotic hypoglycemia, hepatomegaly, and liver dysfunction, typically presenting during intercurrent illness. - Late-onset myopathic form: the most common presentation in the current NBS era — episodic rhabdomyolysis triggered by prolonged exercise, fasting, or illness; muscle cramps, pain, dark urine (myoglobinuria), and markedly elevated creatine kinase (CK).

Practical Actions

Heterozygous carriers (AG genotype) are clinically asymptomatic. The primary practical significance of carrier status is reproductive: if both parents carry ACADVL pathogenic variants, each child has a 25% risk of VLCAD deficiency. Partner carrier testing before or during pregnancy is the key action.

For individuals with biallelic pathogenic variants (AA genotype, or compound heterozygous for two different ACADVL pathogenic alleles), the consensus-based nutrition management guidelines⁶⁶ consensus-based nutrition management guidelines
Vockley et al. 2021, Mol Genet Metab. PMID 33093005 recommend: avoidance of fasting (using age-appropriate maximum fasting intervals), restriction of long-chain fatty acid intake, MCT supplementation as an alternative fat source bypassing the enzymatic block, and carnitine supplementation to support acylcarnitine clearance. During exercise, consuming easily metabolized carbohydrates before and after activity significantly reduces rhabdomyolysis risk.

Interactions

This variant causes disease in the autosomal recessive setting: a second loss-of-function ACADVL variant on the other chromosome must be present. Most affected patients identified through newborn screening are compound heterozygous (two different pathogenic variants) rather than homozygous for p.Gly289Arg. Genotyping at this single SNP position will detect the AG carrier state but cannot determine whether a second pathogenic variant exists elsewhere in ACADVL — full gene sequencing is required for a complete clinical picture in symptomatic individuals or those with positive NBS results.

Alcohol dehydrogenase 1B (ADH1B) catalyzes the first step of alcohol metabolism, converting ethanol into acetaldehyde in the liver. Most people carry the common Arg370 form (ADH1B*1). The ADH1B*2 allele (His48Arg, rs1229984) is common in East Asian populations and encodes an enzyme roughly 100-fold more active than the common form. But there is a third functional variant — ADH1B*3 (Arg370Cys, rs2066702) — that is found almost exclusively in populations of African descent.

ADH1B*3 encodes a superactive enzyme with substantially higher ethanol oxidation kinetics than the common ADH1B*1 form. Like ADH1B*2, it accelerates the conversion of ethanol to acetaldehyde, producing an aversive physiological response that acts as a natural deterrent against heavy drinking. In African American populations, where this allele reaches frequencies of 15–25%, it is one of the strongest genetic predictors of alcohol consumption patterns ever identified.

This variant is functionally and epidemiologically distinct from rs1229984. The two alleles reside at different positions in the ADH1B protein (residue 48 versus residue 370), arise from independent mutational events, are distributed across different populations, and contribute independently to alcohol use disorder risk. A person of African descent may carry ADH1B*3 with no ADH1B*2 allele, and vice versa for East Asians.

The Mechanism

The rs2066702 A allele, on the plus (forward) strand of chromosome 4, corresponds to the Cys370 substitution in the ADH1B protein — the ADH1B*3 allele. The gene is located on the minus strand, so the A allele in genome files is the complement of the T allele in the coding sequence notation used in older literature.

At the protein level, replacing Arginine with Cysteine at position 370 alters the active-site geometry of the enzyme in a way that increases its catalytic efficiency for ethanol oxidation. The result is accelerated production of [acetaldehyde | A reactive aldehyde intermediate; classified as a Group 1 human carcinogen by the IARC; causes flushing, nausea, and tachycardia] after alcohol ingestion — similar in kind to what ADH1B*2 produces in East Asian populations, though the mechanistic basis (different residue, different kinetic parameters) is independent.

Because the downstream enzyme ALDH2, which clears acetaldehyde, operates at a fixed rate, any increase in acetaldehyde production from faster ADH1B activity creates a transient acetaldehyde surplus. Carriers of ADH1B*3 experience faster and more aversive responses to alcohol, which behaviorally reduces both the amount consumed and the likelihood of developing alcohol use disorder.

The Evidence

Genome-wide significance in African Americans:

The first genome-wide association study for maximum number of alcoholic drinks consumed in a 24-hour period in African Americans¹¹ The first genome-wide association study for maximum number of alcoholic drinks consumed in a 24-hour period in African Americans
Xu K et al. Genomewide Association Study for Maximum Number of Alcoholic Drinks in European Americans and African Americans. Alcohol and Alcoholism, 2015 identified rs2066702 as the peak genome-wide significant signal in African Americans (p = 2.50×10⁻¹⁰). Eight SNPs in the region on chromosome 4 reached significance, all tagging the ADH1B*3 haplotype.

A subsequent GWAS of maximum habitual alcohol intake in 17,029 African American veterans from the VA Million Veteran Program²² A subsequent GWAS of maximum habitual alcohol intake in 17,029 African American veterans from the VA Million Veteran Program
Gelernter J et al. Genome-wide Association Study of Maximum Habitual Alcohol Intake in >140,000 U.S. European and African American Veterans. Biological Psychiatry, 2019 confirmed rs2066702 as the lead locus for African Americans (p = 2.3×10⁻¹²), a far stronger signal than any other variant identified in that ancestry group.

Clinical alcohol use metrics:

In a large electronic health record study of 57,677 African American veterans³³ In a large electronic health record study of 57,677 African American veterans
Justice AC et al. Validating Harmful Alcohol Use as a Phenotype for Genetic Discovery Using Phosphatidylethanol and a Polymorphism in ADH1B. Alcohol and Alcoholism, 2018, 34.3% of participants carried at least one A allele (minor allele frequency 19.0%). Carrying the protective A allele was associated with approximately half the odds of high AUDIT-C scores (aOR = 0.54) and an aOR of 0.51 when combining AUDIT-C with ICD-coded alcohol use disorder — demonstrating that the protective effect is clinically meaningful and detectable across multiple measurement approaches.

AUD diagnostic criteria:

Among African American participants in a detailed AUD phenotyping study⁴⁴ Among African American participants in a detailed AUD phenotyping study
Hart AB et al. Which alcohol use disorder criteria contribute to the association of ADH1B with alcohol dependence? Addiction Biology, 2016, individuals homozygous for the major (non-protective) allele GG endorsed significantly more DSM-IV and DSM-5 AUD criteria (p = 1.9×10⁻⁹). The criterion most strongly linked to this variant was tolerance — the need for increasing amounts of alcohol to achieve the desired effect — suggesting that ADH1B*3 carriers develop tolerance more slowly, consistent with the variant's faster acetaldehyde production making high-dose alcohol less pleasant.

Prenatal exposure and developmental protection:

A longitudinal study in African American families⁵⁵ A longitudinal study in African American families
Dodge NC et al. Protective effects of the alcohol dehydrogenase-ADH1B*3 allele on attention and behavior problems in adolescents exposed to alcohol during pregnancy. Alcoholism: Clinical and Experimental Research, 2014 found that maternal ADH1B*3 carrier status shielded adolescent offspring from behavioral and attention consequences of prenatal alcohol exposure, with allele frequencies of 17.6% in mothers and 21.0% in adolescents — consistent with the expected 15–20% frequency in African American populations. The proposed mechanism is that faster maternal alcohol metabolism reduces peak blood alcohol concentration reaching the fetus.

Practical Actions

For GG carriers (most common in non-African populations): Without the ADH1B*3 protective allele, you lack one of the biological deterrents against heavy drinking. If you are of African descent, your GG genotype means you metabolize alcohol at the common rate — higher-tolerance drinking is biologically more accessible to you, which removes a natural brake on consumption. This is relevant when considering whether your drinking patterns are influenced by behavioral versus genetic factors.

For AG and AA carriers (primarily found in people of African descent): Your ADH1B*3 allele accelerates alcohol-to-acetaldehyde conversion, producing faster aversive responses to alcohol. This is one of the strongest inherited protective factors against alcohol use disorder in populations of African ancestry. The biological deterrent is real — but, as with ADH1B*2 in East Asian populations, it can be overridden socially. Environmental factors (peer norms, social offers) can diminish the genetic protection when drinking pressures are high.

Interactions

ADH1B*3 (rs2066702) and ADH1B*2 (rs1229984, His48Arg) reside in the same gene but at different protein positions. They arise independently and distribute across different populations. In African American populations where both alleles may occasionally co-occur, combined diplotype analysis is informative. However, the primary co-variant to consider alongside rs2066702 in African-ancestry individuals is ALDH2 (rs671), which controls the downstream clearance of the acetaldehyde that ADH1B*3 produces more rapidly.

ADH1C variants (rs1693482, rs698) are pathway partners that also affect the rate of alcohol oxidation. Combined diplotype analyses have documented that ADH1B and ADH1C allele combinations affect liver disease risk and alcohol metabolism outcomes beyond either variant alone.

The gastric epithelium is under constant assault — acid, pepsin, ingested pathogens, and the chronic coloniser Helicobacter pylori¹¹ Helicobacter pylori
A gram-negative bacterium that infects the stomach lining of roughly half the global population; the primary causal agent of peptic ulcers and a major risk factor for gastric cancer. The first line of defence is a thick mucus layer anchored by mucin glycoproteins, the most important of which is MUC1²² MUC1
Mucin 1, a high-molecular-weight, heavily O-glycosylated transmembrane protein expressed on the apical surface of gastric epithelial cells; it provides both steric hindrance against pathogens and acts as a releasable decoy. rs2070803 is a regulatory variant near the MUC1 gene on chromosome 1q22 that influences how much of this protective protein the stomach produces. Carrying one or two copies of the A allele is associated with lower MUC1 surface expression — and, in some of the largest genetic studies ever conducted on gastric cancer, a meaningfully elevated risk of developing diffuse-type gastric cancer³³ diffuse-type gastric cancer
One of two major histological subtypes of gastric cancer (alongside intestinal-type); diffuse-type spreads through the stomach wall without forming a distinct mass and carries a worse prognosis.

The Mechanism

rs2070803 maps approximately 585 base pairs upstream of the MUC1 transcription start site on the reverse strand, placing it in the gene's regulatory region. It is in strong linkage disequilibrium⁴⁴ linkage disequilibrium
Non-random co-inheritance of nearby variants; alleles at linked sites are more often inherited together than expected by chance with the functionally characterised variant rs4072037, which directly alters MUC1 promoter activity and controls the ratio of major MUC1 splice variants produced in the gastric epithelium.

Carriers of the A allele at rs2070803 produce less MUC1 protein at the gastric mucosal surface. This reduction compromises the epithelium in two ways. First, MUC1's extracellular domain normally acts as a steric barrier against bacterial adhesion — its dense glycan coat is physically too large to allow most bacteria to reach the underlying cell membrane. Second, MUC1 functions as a releasable decoy: shed extracellular domain fragments bind pathogen adhesins and carry them away from the epithelium. With less surface MUC1, both mechanisms are weakened.

H. pylori further compounds genetically reduced expression. The virulence factor CagA⁵⁵ CagA
Cytotoxin-associated gene A protein, injected directly into gastric epithelial cells by H. pylori; once inside, it is tyrosine-phosphorylated and disrupts multiple host signalling pathways is injected into host cells, where it undergoes phosphorylation and promotes binding of MUC1's cytoplasmic tail to β-catenin. The resulting MUC1–β-catenin complex translocates to the nucleus, activating proliferative gene programmes including cyclin-D1. Carriers who already have lower baseline MUC1 expression due to the A allele are therefore more vulnerable to this CagA-driven oncogenic cascade.

The Evidence

The primary evidence comes from a genome-wide association study⁶⁶ genome-wide association study
Saeki N et al. A functional single nucleotide polymorphism in mucin 1, at chromosome 1q22, determines susceptibility to diffuse-type gastric cancer. Gastroenterology, 2011 conducted across three panels of Japanese and Korean individuals (discovery: 606 cases/1,264 controls; validation 1: 304 cases/1,465 controls; validation 2: 452 cases/372 controls). rs2070803 reached genome-wide significance with p = 4.33 × 10⁻¹³ and a meta-analytic odds ratio of 1.71 for diffuse-type gastric cancer. Notably, the association was specific to diffuse-type and not intestinal-type gastric cancer.

A complementary case-control study⁷⁷ case-control study
Xu L et al. Risk of gastric cancer is associated with the MUC1 568 A/G polymorphism. Int J Oncol, 2009 directly measured MUC1 protein in gastric tissue: AA genotype carriers showed significantly lower MUC1 immunostaining (r = −0.179, p = 0.004) and a 1.81-fold increased gastric cancer risk, providing the functional link between genotype and reduced mucosal protection.

A systematic review and meta-analysis⁸⁸ systematic review and meta-analysis
Giraldi L et al. MUC1, MUC5AC, and MUC6 polymorphisms, Helicobacter pylori infection, and gastric cancer. Eur J Cancer Prev, 2018 of 21 studies confirmed the protective effect of the G allele (OR 0.66, 95% CI 0.57–0.78 for dominant model AG/GG vs. AA), with consistent findings across Asian (OR 0.73) and White European (OR 0.48) populations.

The risk is further amplified when rs2070803 co-occurs with the PSCA risk variant rs2294008. Carriers of risk alleles at both loci face a dramatically higher combined gastric cancer risk, as these two genes act in partially overlapping mucosal defence pathways.

Practical Implications

This variant is a genuine gastric cancer susceptibility signal — not a certainty, but a meaningful elevation in lifetime risk that is actionable. The most direct intervention is targeted H. pylori screening, since the genetic risk is substantially mediated through the bacteria's ability to exploit weakened mucosal defences. Current evidence suggests that eradicating H. pylori reduces gastric cancer incidence by roughly 35–45% in infected individuals, and for A allele carriers the absolute benefit may be larger because the residual mucosal vulnerability is genetically amplified.

Dietary and supplement strategies that support mucosal integrity — specifically those with evidence in the gastric context — complement surveillance without replacing it. Antral gastroscopy⁹⁹ gastroscopy
Direct visual inspection of the stomach lining using an endoscope surveillance intervals recommended by gastroenterologists should be followed by anyone who also has chronic gastritis, intestinal metaplasia, or a family history of gastric cancer.

Interactions

rs2070803 is in strong linkage disequilibrium with rs4072037, the functionally characterised MUC1 promoter variant. These two SNPs tag the same haplotype in most studies and their associations are not independent — the risk captured by rs2070803 is largely the same risk captured by rs4072037.

The PSCA variant rs2294008 represents a separate pathway (prostate stem cell antigen, expressed in gastric epithelium) that interacts epistatically with MUC1 variants. Carriers of both MUC1 and PSCA risk alleles face substantially higher combined risk than either alone, as documented in the original Saeki et al. GWAS.

ABCG2 — also called Breast Cancer Resistance Protein (BCRP) — is one of the most versatile efflux pumps in the body. It sits at the apical surface of intestinal cells, renal tubules, and the blood–brain barrier, where it exports a wide range of substances including uric acid¹¹ uric acid
a metabolic waste product of purine breakdown, porphyrins, anticancer drugs, antibiotics, and antiretroviral medications. The rs2231137 variant encodes a valine-to-methionine substitution at position 12 of the protein — a residue in the first transmembrane segment that influences how ABCG2 folds and reaches the cell membrane.

The Mechanism

The V12M change (T allele on the plus strand; the protein letter change is coded on the minus strand as G>A at nucleotide 34 of the coding sequence) sits at the very beginning of the ABCG2 protein's first predicted transmembrane helix. One cell model study found ²² Kamo et al., Intl J Cancer, 2004 that V12M disrupts apical plasma membrane localization — the protein is synthesized normally but fails to traffic to the correct compartment. Cells expressing V12M showed drug efflux less than one-tenth that of wild-type. However, a second study using membrane vesicles from HEK293 cells ³³ Kondo et al., Pharm Res, 2004 found transport activity for estrone sulfate, DHEAS, and methotrexate was comparable to wild-type. The discrepancy likely reflects cell-type and assay differences, making V12M's intrinsic functional impact harder to pin down than the better-characterised Q141K variant (rs2231142), which consistently reduces urate transport by ~53%.

The Evidence

Population genetics paints an interesting picture. The T allele (Met12) occurs at about 4% in Europeans but reaches 27% in East Asians and 23% in Latino/Admixed American populations — a striking frequency difference suggesting different selective pressures across ancestries.

A meta-analysis of 52 studies⁴⁴ meta-analysis of 52 studies
Shi et al., BMC Med Genet, 2020 found that carrying one or two T alleles at rs2231137 was associated with 36–57% lower odds of gout compared to CC homozygotes. This protective direction for gout is somewhat counterintuitive if V12M reduces urate transport, and may reflect incomplete LD with nearby protective haplotypes, population stratification, or context-dependent functional effects.

In drug-handling contexts, the picture is different. A study of 149 HIV-infected patients ⁵⁵ Rodrigues et al., Mol Genet Genomic Med, 2024 found that the T allele and the heterozygous CT genotype were associated with increased risk of antiretroviral-induced hepatotoxicity (OR 1.50 for the allele; haplotype OR up to 2.49 in combination with rs2231142). In a small study of 93 Iranian children, ⁶⁶ Barakat et al., Seizure, 2022 each T allele was associated with approximately 2.4-fold higher odds of drug-resistant epilepsy, suggesting altered antiepileptic drug transport.

An epistatic interaction study in 4,914 Chinese participants ⁷⁷ Tang et al., Hereditas, 2020 found that rs2231137 interacts with the PKD2 variant rs2728121 to influence urate levels and gout risk, with stronger effects in males (Pint = 0.004).

Practical Actions

The main clinical implications of this variant are in the context of specific drugs whose clearance depends on ABCG2 — particularly antiretrovirals used in HIV treatment and certain antiepileptic drugs. Carriers of the T allele, especially those also carrying risk alleles at the companion ABCG2 variant rs2231142 (Q141K), may have a compounded reduction in ABCG2 transport capacity that warrants monitoring of drug levels and liver enzymes when starting hepatically-cleared medications.

Interactions

The most clinically important interaction is with rs2231142 (Q141K), the dominant functional variant in ABCG2. Q141K alone reduces urate transport by ~53% and drives most of the ABCG2-gout association. Carrying T alleles at both rs2231137 (V12M) and rs2231142 (Q141K) may compound transporter impairment beyond either variant alone — a haplotype combination studied for drug resistance in cancer cells (PMID 40806557). The 12M/141K haplotype showed 10.7-fold resistance to the anticancer drug mitoxantrone, substantially higher than either variant alone.

There is also a documented epistatic interaction with rs2728121 in the PKD2 gene, which co-regulates urate levels and gout susceptibility through separate renal mechanisms.